Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
24
EPIX Quote, Financials, Valuation and Earnings
Last price:
$1.61
Seasonality move
:
35.98%
Day range:
$1.58 - $1.64
52-week range:
$1.40 - $11.67
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.57x
Volume:
245.3K
Avg. volume:
373.3K
1-year change:
-73.77%
Market cap:
$71M
Revenue:
--
EPS (TTM):
-$0.64
Analysts' Opinion
-
Consensus RatingESSA Pharma has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, ESSA Pharma has an estimated upside of 492.85% from its current price of $1.60.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $1.60.
Fair Value
-
According to the consensus of 0 analysts, ESSA Pharma has 492.85% upside to fair value with a price target of -- per share.
EPIX vs. S&P 500
-
Over the past 5 trading days, ESSA Pharma has underperformed the S&P 500 by -0.46% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
ESSA Pharma does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ESSA Pharma has grown year-over-year revenues for 0 quarters straight. In the most recent quarter ESSA Pharma reported revenues of --.
Earnings Growth
-
ESSA Pharma has grown year-over-year earnings for 0 quarters straight. In the most recent quarter ESSA Pharma reported earnings per share of -$0.14.
Enterprise value:
-55.7M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
2.45x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$37M | -$32.1M | -$34.2M | -$6.8M | -$7M | |
| EBITDA | -$34.9M | -$26.5M | -$28.5M | -$5.5M | -$6.3M | |
| Diluted EPS | -$0.80 | -$0.60 | -$0.64 | -$0.12 | -$0.14 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $80.3M | $197.6M | $169.1M | $148.8M | $127.6M | |
| Total Assets | $80.6M | $198.2M | $169.5M | $149.1M | $128.1M | |
| Current Liabilities | $1.2M | $3.9M | $2.3M | $3.5M | $3.3M | |
| Total Liabilities | $1.3M | $4.2M | $2.4M | $3.5M | $3.5M | |
| Total Equity | $79.2M | $194M | $167.1M | $145.6M | $124.6M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$28M | -$19.8M | -$22.7M | -$4.5M | -$3.4M | |
| Cash From Investing | -$53.1M | -$3.5M | $91.8M | -$264.7K | $21M | |
| Cash From Financing | $252.7K | -$68.2K | $925.5K | -$13.7K | $59.7K | |
| Free Cash Flow | -$28M | -$19.8M | -$22.7M | -$4.5M | -$3.4M | |
EPIX
Sector
Market Cap
$71M
$44.6M
Price % of 52-Week High
13.71%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.68%
1-Year Price Total Return
-73.77%
-29.09%
Beta (5-Year)
1.624
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$1.63
200-day SMA
Sell
Level
$5.40
Bollinger Bands (100)
Sell
Level
2.33 - 6.27
Chaikin Money Flow
Buy
Level
52M
20-day SMA
Sell
Level
$1.70
Relative Strength Index (RSI14)
Sell
Level
23.82
ADX Line
Sell
Level
9.81
Williams %R
Buy
Level
-85.7143
50-day SMA
Sell
Level
$2.92
MACD (12, 26)
Sell
Level
-0.30
25-day Aroon Oscillator
Sell
Level
-68
On Balance Volume
Neutral
Level
63M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (6)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.
Stock Forecast FAQ
In the current month, EPIX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The EPIX average analyst price target in the past 3 months is --.
-
Where Will ESSA Pharma Stock Be In 1 Year?
According to analysts, the consensus estimate is that ESSA Pharma share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About ESSA Pharma?
Analysts are divided on their view about ESSA Pharma share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ESSA Pharma is a Sell and believe this share price will drop from its current level to --.
-
What Is ESSA Pharma's Price Target?
The price target for ESSA Pharma over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is EPIX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ESSA Pharma is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of EPIX?
You can purchase shares of ESSA Pharma via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ESSA Pharma shares.
-
What Is The ESSA Pharma Share Price Today?
ESSA Pharma was last trading at $1.61 per share. This represents the most recent stock quote for ESSA Pharma. Yesterday, ESSA Pharma closed at $1.60 per share.
-
How To Buy ESSA Pharma Stock Online?
In order to purchase ESSA Pharma stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
